{"entity":{"id":"nct07362940","kind":"trial","name":"A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib","aka":[],"tldr":"A phase 1/2 trial of GEN-725 tablets + Dositinib mesylate tablets in non-small-cell lung cancer, run by Henan Genuine Biotech Co., Ltd., now recruiting.","summary":"A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib is a phase 1/2 interventional study registered as NCT07362940 by Henan Genuine Biotech Co., Ltd., with 110 participants planned, started 2025-11-27 and due to reach its primary completion in 2027-07-31. Interventions recorded: GEN-725 tablets + Dositinib mesylate tablets.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07362940","url":"https://clinicaltrials.gov/study/NCT07362940"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07362940","phase":"1/2","setting":"A Phase Ⅰ/Ⅱa Clinical Study Evaluating the Efficacy and Safety of GEN-725 in Combination With Dositinib in Patients With Locally Advanced or Metastatic EGFR-Mutant Non-small Cell Lung Cancer","sponsor":"Henan Genuine Biotech Co., Ltd.","enrolled":110,"outcomes":[]},"route":"/trials/nct07362940/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"company":[{"id":"henan-genuine-biotech","kind":"company","name":"Henan Genuine Biotech","route":"/companies/henan-genuine-biotech/"}]}}